Close Menu

The president and CEO of the Biotechnology Industry Organization, James Greenwood, tells the Boston Globe that the biotech companies will, for the most part, survive the recession. As a whole, he says, the industry has just started to make money, though because of the economy, there is a risk of some companies losing out. Greenwood also discusses generic biologics and data exclusivity as well as healthcare reform.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Russia says its candidate SARS-CoV-2 vaccine has a very high efficacy rate in an initial analysis of clinical trial data, according to the Financial Times.

Wired reports on a microbial analysis of sketches drawn by Leonardo DaVinci.

A new survey explores coronavirus vaccine hesitancy among Black and Latino individuals, the Washington Post reports.

In Nucleic Acids Research this week: the Aging Atlas database, a database of human metagenome-related metadata, and more.